Predict your next investment

Inversago Pharma company logo
HEALTHCARE | Drug Development
inversago.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series B | Alive

Total Raised

$40.34M

Last Raised

$35M | 1 yr ago

About Inversago Pharma

Inversago Pharma is a specialized, preclinical-stage biotech company that develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), Type-1 Diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).

Inversago Pharma Headquarter Location

1010 Sherbrooke Ouest Suite 1800

Montreal, Quebec, H3A 2A7,

Canada

Latest Inversago Pharma News

LoA Update: Inversago’s Prader-Willi Syndrome trial sees seven-point spike in chances to transition to next stage after Phase I status update

Jun 17, 2021

By William Newton 17 Jun 2021 (Last Updated June 17th, 2021 15:00) Inversago Pharma’s Phase I asset MRI-1867 for Prader-Willi Syndrome (PWS) saw its Phase Transition Success Rate (PTSR) jump seven points to 70%. Montreal, Canada-based Inversago enrolled 40 patients in the placebo-controlled, single-ascending dose Phase I study. Share Article Inversago Pharma’s Phase I asset MRI-1867 for Prader-Willi Syndrome (PWS) saw its Phase Transition Success Rate (PTSR) jump seven points to 70%. The PTSR update occurred on 14 June, on the heels of the Phase I’s ClinicalTrials.gov listing changing the trial’s status to completed on 10 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. Montreal, Canada-based Inversago enrolled 40 patients in the placebo-controlled, single-ascending dose Phase I study. On 10 June, the trial’s ClinicalTrials.gov listing was changed to state the Phase I completed on 16 May. PWS, a genetic disorder affecting chromosome 15, can cause short stature and behavioural and intellectual disabilities. MRI-1867 is a cannabinoid receptor type 1 antagonist. The Phase I update resulted in a modest one-point bump to the drug’s Likelihood of Approval (LoA), which rose to 12%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type. William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData . Related Companies

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Inversago Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Inversago Pharma is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cannabis

3,519 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

B

Biopharmaceuticals

7,147 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,734 items

Inversago Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Inversago Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.